Asteromorph
Category: AI in Biotech / Drug Discovery
Seoul-based AI-for-science lab building 'Spacer,' a foundation model that autonomously generates and validates original scientific hypotheses in biology and chemistry. Asteromorph was founded in 2025. The company is led by Lee Min-hyung (이민형). Based in Seoul, South Korea. Team size: 11-50. Total funding raised: $31.4M. Latest round: Seed. Key investors include BonAngels Venture Partners, Future Play, Korea Investment Partners, Mirae Asset Venture Investment, Mirae Asset Capital, IMM Investment, Premier Partners, Korea Development Bank, KDB Capital, SV Investment, STIC Ventures.
- Founded
- 2025
- Headquarters
- Seoul, South Korea
- Team size
- 11-50
- Total funding
- $31.4M
Value proposition
Spacer mathematically models the process of generating novel scientific ideas so the AI itself has emergent research creativity, rather than relying on human-guided idea generation as in prior 'AI Scientist' approaches from Google and Sakana AI.
Products and solutions
Spacer — a scientific reasoning/discovery foundation model that generates original research hypotheses in biology and chemistry, multimodal reasoning system that scored gold-medal level on the 56th IPhO 2026 theory exam (28.6/30)
Unique value
First Korean startup pursuing 'scientific superintelligence'; designed to generate hundreds of new scientific hypotheses per day autonomously rather than acting as a human-assisted research copilot
Target customer
Biotech/pharma R&D teams, scientific research institutions, and (long-term) any organization needing accelerated hypothesis generation and experimental design
Industries served
Biotech / Drug Discovery, Scientific Research, Life Sciences
Technology advantage
Proprietary Spacer architecture claims to mathematically implement the generative process behind novel scientific ideas (published as a technical report/preprint 'Spacer: Towards Engineered Scientific Inspiration' on arXiv, Aug 2025); young research team drawn from Korean Science High School / Seoul National University gifted-education pipeline including International Olympiad medalists
How they differentiate
Positions itself against 'AI co-scientist' tools that still rely on human intuition for research originality/experimental design, claiming Spacer has emergent, self-directed scientific idea generation
Main competitors
Google DeepMind (AI co-scientist), Sakana AI (AI Scientist), FutureHouse (autonomous science agents)
Major milestones
Achieved gold-medal-level score (28.6/30) on the 56th International Physics Olympiad (IPhO) theory exam using its multimodal AI system (Aug 2026), published 'Spacer: Towards Engineered Scientific Inspiration' tech report on arXiv proposing an AI-generated hepatocellular carcinoma suppression hypothesis (Aug 2025), raised ₩5B seed (Apr 2025) then ₩42B seed extension (May 2026) for cumulative ₩47B, CEO briefly appointed PD of the government's 'K-Moonshot' AI Scientist mission before resigning amid a credentials controversy (June 2026), remaining as company CEO
Growth metrics
Grew from 0 to 20+ employees within its first year (Feb 2025–2026); raised cumulative ₩47B (~$31.4M) in seed funding within ~15 months of founding
Market positioning
Only Korean startup explicitly targeting 'scientific superintelligence'; positioned as a frontier science-AI lab competing globally against much larger, better-funded labs (Google DeepMind, Sakana AI, FutureHouse)
Geographic focus
Global (frontier AI-for-science race), headquartered and initially funded in South Korea
Patents and IP
Technical report 'Spacer: Towards Engineered Scientific Inspiration' published on arXiv (Aug 25, 2025); no granted patents publicly disclosed
About Lee Min-hyung (이민형)
Joined Seoul National University Medical School's System Immunology Research Institute as a research assistant at age 16 (contested by some researchers as inflated); skipped high school and undergraduate study to enter Seoul National University College of Pharmacy's MS-PhD integrated program before taking leave to found Asteromorph in Feb 2025. Briefly appointed PD (mission manager) of Korea's government-led 'K-Moonshot' AI Scientist project in May 2026, then resigned in June 2026 amid public controversy over his credentials, remaining as Asteromorph CEO throughout (confirmed by July 30, 2026 and Aug 31, 2026 reporting).
Latest news about Asteromorph
More AI in Biotech / Drug Discovery companies
Official website: https://asteromorph.com
